Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer

被引:32
|
作者
Takamori, Shinkichi [1 ]
Toyokawa, Gouji [1 ]
Okamoto, Isamu [2 ]
Takada, Kazuki [1 ,3 ]
Kozuma, Yuka [1 ]
Matsubara, Taichi [1 ]
Haratake, Naoki [1 ]
Akamine, Takaki [1 ]
Katsura, Masakazu [1 ]
Mukae, Nobutaka [4 ]
Shoji, Fumihiro [1 ]
Okamoto, Tatsuro [1 ]
Oda, Yoshinao [3 ]
Iwaki, Toru [5 ]
Iihara, Koji [4 ]
Nakanishi, Yoichi [2 ]
Maehara, Yoshihiko [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8128582, Japan
[2] Kyushu Univ, Chest Grad Sch Med Sci, Res Inst Dis, Fukuoka, Japan
[3] Kyushu Univ, Dept Anat Pathol, Grad Sch Med Sci, Fukuoka, Japan
[4] Kyushu Univ, Dept Neurosurg, Grad Sch Med Sci, Fukuoka, Japan
[5] Kyushu Univ, Dept Neuropathol, Neurol Inst, Grad Sch Med Sci, Fukuoka, Japan
关键词
Programmed cell death-ligand 1; immunotherapy; non-small cell lung cancer; BRAIN METASTASES; PREDICTIVE BIOMARKERS; EXPRESSION; PD-L1; PEMBROLIZUMAB; ALECTINIB; NIVOLUMAB; ERLOTINIB; CHEMOTHERAPY; CRIZOTINIB;
D O I
10.21873/anticanres.11813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To investigate the discordance in the programmed cell death-ligand 1 (PD-L1) expression between primary and metastatic tumors and analyze the association between the discordance and the clinical factors in non-small cell lung cancer (NSCLC) patients. Patients and Methods: Twenty-one NSCLC patients who underwent surgery or biopsy for paired primary and metastatic lesions at our Institution from 2005 to 2016 were analyzed. Lesions with the PD-L1 expression being >= 5% were considered PD-L1-positive. Results: The metastatic sites included the brain (n=16), adrenal gland (n=3), spleen (n=1) and jejunum (n=1). Negative conversion of the primary PD-L1-positive NSCLC and positive conversion of the primary PD-L1-negative NSCLC were observed in 3 (14%) and 2 (10%) cases, respectively. Radiotherapy for the metastatic brain lesion before its resection showed a significant relationship with the positive conversion of the primary PD-L1-negative NSCLC (p=0.048). Conclusion: Radiotherapy-derived effects may contribute to the positive conversion of the primary PD-L1-negative NSCLC.
引用
收藏
页码:4223 / 4228
页数:6
相关论文
共 50 条
  • [1] Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancer
    Kian, Waleed
    Roisman, Laila C.
    Wallach, Nadav
    Levitas, Dina
    Yakobson, Alexander
    Dudnik, Yulia
    Peled, Nir
    Rouvinov, Keren
    JOURNAL OF THORACIC DISEASE, 2020, 12 (08) : 3918 - 3920
  • [2] Consistency Analysis of Programmed Death-Ligand 1 Expression between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study
    Luo, Luqiao
    Luo, Xinlan
    Chen, Wendan
    Liang, Chunyan
    Yao, Su
    Huang, Weihong
    Liu, Chao
    Ge, Yan
    Lin, Xingtao
    Li, Zhi
    JOURNAL OF CANCER, 2020, 11 (04): : 974 - 982
  • [3] Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization
    Kim, Hye Ryun
    Cha, Yoon Jin
    Hong, Min Hee
    Gandhi, Manoj
    Levinson, Shauna
    Jung, Inkyung
    Lee, Jin Gu
    Lee, Chang Young
    Cho, Byoung Chul
    Ha, Sang-Jun
    Shim, Hyo Sup
    ONCOTARGET, 2017, 8 (50) : 87234 - 87243
  • [4] Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
    Iafolla, Marco A. J.
    Juergens, Rosalyn A.
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [5] Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice
    Mino-Kenudson, Mari
    CANCER CYTOPATHOLOGY, 2017, 125 (07) : 521 - 528
  • [6] Heterogeneity of programmed death-ligand 1 expression and infiltrating lymphocytes in paired resected primary and metastatic non-small cell lung cancer
    Wu, Jianghua
    Sun, Wei
    Yang, Xin
    Wang, Haiyue
    Liu, Xinying
    Chi, Kaiwen
    Zhou, Lixin
    Huang, Xiaozheng
    Mao, Luning
    Zhao, Shuai
    Ding, Tingting
    Meng, Bin
    Lin, Dongmei
    MODERN PATHOLOGY, 2022, 35 (02) : 218 - 227
  • [7] Relationship Between Programmed Death-ligand 1 and Clinicopathological Characteristics in Non-small Cell Lung Cancer Patients
    Yan-yan Chen
    Liu-bo Wang
    Hui-li Zhu
    Xiang-yang Li
    Yan-ping Zhu
    Yu-lei Yin
    Fan-zhen Lü
    Zi-li Wang
    Jie-ming Qu
    Chinese Medical Sciences Journal, 2013, 28 (03) : 147 - 151
  • [8] Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
    Khunger, Monica
    Rakshit, Sagar
    Pasupuleti, Vinay
    Hernandez, Adrian V.
    Mazzone, Peter
    Stevenson, James
    Pennell, Nathan A.
    Velcheti, Vamsidhar
    CHEST, 2017, 152 (02) : 271 - 281
  • [9] Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
    Nam, Chang Hyun
    Koh, Jaemoon
    Ock, Chan-Young
    Kim, Miso
    Keam, Bhumsuk
    Kim, Tae Min
    Jeon, Yoon Kyung
    Kim, Dong-Wan
    Chung, Doo Hyun
    Heo, Dae Seog
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2021, 36 (04): : 975 - +
  • [10] Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer
    Dong, Zhengwei
    Liu, Yiwei
    Jiang, Tao
    Hou, Likun
    Wu, Fengying
    Gao, Guanghui
    Li, Xuefei
    Zhao, Chao
    Wang, Yan
    Yang, Shuo
    Mao, Shiqi
    Liu, Qian
    Li, Yumei
    Xu, Chuan
    Wu, Chunyan
    Ren, Shengxiang
    Zhou, Caicun
    Zhang, Jun
    Hirsch, Fred R.
    JOURNAL OF CANCER, 2020, 11 (03): : 551 - 558